The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

<p><strong>Objective:</strong> Post hoc analysis of pooled data from 9 randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis [RA] and psoriatic arthritis [PsA]) on residual pain in patients with RA or PsA...

Full description

Bibliographic Details
Main Authors:	Dougados, M, Taylor, P, Bingham III, CO, Fallon, L, Brault, Y, Roychoudhury, S, Wang, L, Kessouri, M
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2022

Similar Items

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Maxime Dougados, et al.
Published: (2022-11-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
by: Dougados, M, et al.
Published: (2020)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2018)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
by: Burmester, GR, et al.
Published: (2023)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
by: Taylor, P, et al.
Published: (2019)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2018)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-12-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2024-01-01)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
by: Taylor, PC, et al.
Published: (2020)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2021)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
by: de Vlam, K, et al.
Published: (2022)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
by: Céleste J.T. van der Togt, et al.
Published: (2022-12-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
by: Helliwell, P, et al.
Published: (2018)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01)

Pathogenesis of chronic chikungunya arthritis: resemblances and links with rheumatoid arthritis
by: Amaral, JK, et al.
Published: (2022)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Use of YAKVINUS® (tofacitinib) for the treatment of rheumatoid arthritis
by: article Editorial
Published: (2018-06-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
by: Karen E. Hansen, et al.
Published: (2022-12-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
by: Mahta Mortezavi, et al.
Published: (2023-06-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
by: Coates, L, et al.
Published: (2016)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
by: Kawalec P, et al.
Published: (2017-12-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
by: Nash, P, et al.
Published: (2018)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
by: Francesca Romana Spinelli, et al.
Published: (2023-09-01)

Tofacitinib in baseline treatment of rheumatoid arthritis: own clinical experience
by: A. R. Babaeva, et al.
Published: (2016-12-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
by: Bertoldi I, et al.
Published: (2021-07-01)